Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma

J Clin Oncol. 2016 Apr 20;34(12):e104-6. doi: 10.1200/JCO.2013.51.3572. Epub 2014 Oct 13.

Authors

Mark J Smyth¹, Hideo Yagita², Grant A McArthur³

Affiliations

¹ Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria; Queensland Institute of Medical Research; School of Medicine, University of Queensland, Herston, Queensland, Australia.
² Juntendo University School of Medicine, Tokyo, Japan.
³ Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria [email protected].

PMID: 25311221
DOI: 10.1200/JCO.2013.51.3572

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't
Retracted Publication

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Neoplasms / drug therapy*
Bone Neoplasms / genetics
Bone Neoplasms / immunology
Bone Neoplasms / secondary
Brain Neoplasms / secondary
Brain Neoplasms / surgery
CTLA-4 Antigen / antagonists & inhibitors*
CTLA-4 Antigen / immunology
Denosumab / therapeutic use*
Female
Humans
Ipilimumab
Lymphatic Metastasis
Melanoma / drug therapy*
Melanoma / genetics
Melanoma / immunology
Melanoma / secondary
Positron-Emission Tomography
Proto-Oncogene Proteins B-raf / genetics
RANK Ligand / antagonists & inhibitors*
RANK Ligand / immunology
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics
Skin Neoplasms / immunology
Skin Neoplasms / pathology
Time Factors
Treatment Outcome
Whole Body Imaging / methods

Substances

Antibodies, Monoclonal
CTLA-4 Antigen
CTLA4 protein, human
Ipilimumab
RANK Ligand
TNFSF11 protein, human
Denosumab
BRAF protein, human
Proto-Oncogene Proteins B-raf